Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ADC Therapeutics stock

Learn how to easily invest in ADC Therapeutics stock.

ADC Therapeutics is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. ADC Therapeutics employs 317 staff and has a trailing 12-month revenue of around $182.4 million.

How to buy ADC Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ADCT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for all-in-one investing

M1 Finance

  • Commission-free stock and ETF trades
  • No management fees
  • Customizable portfolios with automatic rebalancing

ADC Therapeutics stock price (NYSE: ADCT)

Use our graph to track the performance of ADCT stocks over time.

ADC Therapeutics shares at a glance

Information last updated 2023-06-04.
Latest market close$2.49
52-week range$1.85 - $10.88
50-day moving average $2.19
200-day moving average $3.88
Wall St. target price$10.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.54

Buy ADC Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
M1 Finance
Stocks, ETFs
Get $75 - $500
when you sign up and deposit min. $10,000 within 14 days. Terms and conditions apply
Build a custom portfolio of stocks and ETFs with automatic rebalancing.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Earn a 5.4% yield with government-backed Treasury bills.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy ADC Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ADC Therapeutics price performance over time

Historical closes compared with the close of $2.49 from 2023-06-02

1 week (2023-05-26) 9.21%
1 month (2023-05-05) 27.04%
3 months (2023-03-03) -20.70%
6 months (2022-12-05) -29.06%
1 year (2022-06-03) -65.42%
2 years (2021-06-04) -88.68%
3 years (2020-06-05) 34.95
5 years (2018-06-01) N/A

ADC Therapeutics financials

Revenue TTM $182.4 million
Gross profit TTM $35.1 million
Return on assets TTM -16.03%
Return on equity TTM -198.22%
Profit margin -108.86%
Book value $0.47
Market capitalisation $200.8 million

TTM: trailing 12 months

ADC Therapeutics share dividends

We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.

ADC Therapeutics share price volatility

Over the last 12 months, ADC Therapeutics's shares have ranged in value from as little as $1.85 up to $10.88. A popular way to gauge a stock's volatility is its "beta".

ADCT.US volatility(beta: 1.11)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ADC Therapeutics's is 1.1057. This would suggest that ADC Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

ADC Therapeutics overview

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD"dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B. V. , Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited.

Frequently asked questions

What percentage of ADC Therapeutics is owned by insiders or institutions?
Currently 32.603% of ADC Therapeutics shares are held by insiders and 64.314% by institutions.
How many people work for ADC Therapeutics?
Latest data suggests 317 work at ADC Therapeutics.
When does the fiscal year end for ADC Therapeutics?
ADC Therapeutics's fiscal year ends in September.
Where is ADC Therapeutics based?
ADC Therapeutics's address is: Biopole, Epalinges, Switzerland, 1066
What is ADC Therapeutics's ISIN number?
ADC Therapeutics's international securities identification number is: CH0499880968

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site